Log In
Print
BCIQ
Print
Print this Print this
 

Tozadenant (SYN115)

Also known as: SYN-115

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSelective adenosine A2A receptor (ADORA2A) antagonist
Molecular Target Adenosine A2A receptor (ADORA2A)
Mechanism of ActionAdenosine A2A receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD); Treat Parkinson's disease in levodopa-treated patients experiencing end-of-dose wearing off
Regulatory Designation U.S. - Special Protocol Assessment (Treat Parkinson's disease (PD))
Partner Biotie Therapies Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$131.9M

0

$725.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today